晚期CKD中RAS阻断治疗的应用:NKF-KDOQI争议报告
本报告由NKF-KDOQI发布,讨论晚期CKD(eGFR<30mL/min/1.73m2)患者使用RAS阻断的争议。多数临床试验排除了此类患者,RAS阻断起始常伴eGFR急性下降但可能长期保肾。结论是需更多研究评估晚期CKD中RAS阻断的治疗指数。
要点
- 晚期CKD患者使用RAS阻断的证据主要来自排除该人群的试验。
- RAS阻断起始常见eGFR急性下降,可能为功能性且与长期保肾相关。
- 需更多研究评估晚期CKD中RAS阻断的治疗指数。
核心结论
- 需更多研究评估晚期CKD患者RAS阻断的治疗指数。
研究设计与样本
- NKF-KDOQI争议报告,综述已发表数据并讨论RAS阻断在晚期CKD中的应用争议。
主要发现
- 多数临床试验排除了eGFR<30mL/min/1.73m2的晚期CKD患者。
- RAS阻断起始常伴eGFR急性下降,但可能通过降低肾小球内毛细血管压长期保肾。
关键数值与推荐
- 晚期CKD定义为eGFR<30mL/min/1.73m2。
临床怎么用
- 晚期CKD患者使用RAS阻断需权衡eGFR急性下降与长期保肾获益。
局限性
- 缺乏专门针对晚期CKD患者的临床试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple clinical trials have demonstrated that renin-angiotensin system (RAS) blockade with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers effectively reduces chronic kidney disease (CKD) progression. However, most clinical trials excluded participants with advanced CKD (ie, estimated glomerular filtration rate [eGFR]<30mL/min/1.73m2). It is acknowledged that initiation of RAS blockade is often associated with an acute reduction in eGFR, which is thought to be functional, but may result in long-term preservation of kidney function through the reductions in glomerular intracapillary pressure conferred by these agents. In this National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) report, we discuss the controversies regarding use of RAS blockade in patients with advanced kidney disease. We review available published data on this topic and provide perspective on the impact of RAS blockade on changes in eGFRs and potassium levels. We conclude that more research is needed to evaluate the therapeutic index of RAS blockade in patients with advanced CKD.
引用
- Weir MR, Lakkis JI, Jaar B, et al. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. Am J Kidney Dis. 2018. PMID: 30201547. doi:10.1053/j.ajkd.2018.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。